Becker's Healthcare January 14, 2025
Alexandra Murphy

AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company’s key schizophrenia drug, emraclidine, The Wall Street Journal reported Jan. 10.

The write down comes after emraclidine missed crucial goals in two mid-stage trials, prompting AbbVie to reassess the drug’s value. In November, the company revealed that the drug failed to meet...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Arcadia Launches AI-Powered Precision Medicine Solution
Drug Price Negotiation Requires Oversight To Protect Older Americans
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
5 questions facing emerging biotech in 2025
FTC releases second report slamming pharmacy benefit managers

Share This Article